Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology.
Journal
Nature genetics
ISSN: 1546-1718
Titre abrégé: Nat Genet
Pays: United States
ID NLM: 9216904
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
received:
25
09
2023
accepted:
01
05
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
18
6
2024
Statut:
aheadofprint
Résumé
Tumor genomic profiling is increasingly seen as a prerequisite to guide the treatment of patients with cancer. To explore the value of whole-genome sequencing (WGS) in broadening the scope of cancers potentially amenable to a precision therapy, we analysed whole-genome sequencing data on 10,478 patients spanning 35 cancer types recruited to the UK 100,000 Genomes Project. We identified 330 candidate driver genes, including 74 that are new to any cancer. We estimate that approximately 55% of patients studied harbor at least one clinically relevant mutation, predicting either sensitivity or resistance to certain treatments or clinical trial eligibility. By performing computational chemogenomic analysis of cancer mutations we identify additional targets for compounds that represent attractive candidates for future clinical trials. This study represents one of the most comprehensive efforts thus far to identify cancer driver genes in the real world setting and assess their impact on informing precision oncology.
Identifiants
pubmed: 38890488
doi: 10.1038/s41588-024-01785-9
pii: 10.1038/s41588-024-01785-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust
ID : 214388
Pays : United Kingdom
Organisme : Wellcome Trust (Wellcome)
ID : 227000/Z/23/Z
Organisme : Cancer Research UK (CRUK)
ID : C1298/A8362
Informations de copyright
© 2024. The Author(s).
Références
Topol, E. J. Individualized medicine from pre-womb to tomb. Cell 157, 241–253 (2014).
pubmed: 24679539
pmcid: 3995127
doi: 10.1016/j.cell.2014.02.012
Schwartzberg, L., Kim, E. S., Liu, D. & Schrag, D. Precision oncology: who, how, what, when and when not? Am. Soc. Clin. Oncol. Educ. Book 37, 160–169 (2017).
pubmed: 28561651
doi: 10.1200/EDBK_174176
Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719–724 (2009).
pubmed: 19360079
pmcid: 2821689
doi: 10.1038/nature07943
Martínez-Jiménez, F. et al. A compendium of mutational cancer driver genes. Nat. Rev. Cancer 20, 555–572 (2020).
pubmed: 32778778
doi: 10.1038/s41568-020-0290-x
Chakravarty, D. & Solit, D. B. Clinical cancer genomic profiling. Nat. Rev. Genet. 22, 483–501 (2021).
pubmed: 33762738
doi: 10.1038/s41576-021-00338-8
Cheng, D. T. et al. Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251–264 (2015).
pubmed: 25801821
pmcid: 5808190
doi: 10.1016/j.jmoldx.2014.12.006
Redig, A. J. & Jänne, P. A. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J. Clin. Oncol. 33, 975–977 (2015).
pubmed: 25667288
doi: 10.1200/JCO.2014.59.8433
Hyman, D. M., Taylor, B. S. & Baselga, J. Implementing genome-driven oncology. Cell 168, 584–599 (2017).
pubmed: 28187282
pmcid: 5463457
doi: 10.1016/j.cell.2016.12.015
Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).
pubmed: 28481359
pmcid: 5461196
doi: 10.1038/nm.4333
Cuppen, E. et al. Implementation of whole-genome and transcriptome sequencing into clinical cancer care. JCO Precis Oncol. 6, e2200245 (2022).
pubmed: 36480778
pmcid: 10166391
doi: 10.1200/PO.22.00245
Turnbull, C. et al. The 100 000 Genomes Project: bringing whole genome sequencing to the NHS. Br. Med. J. 361, k1687 (2018).
doi: 10.1136/bmj.k1687
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).
doi: 10.1038/s41586-020-1969-6
Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 173, 371–385 (2018).
pubmed: 29625053
pmcid: 6029450
doi: 10.1016/j.cell.2018.02.060
Wang, K. et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat. Genet. 46, 573–582 (2014).
pubmed: 24816253
doi: 10.1038/ng.2983
Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 578, 122–128 (2020).
pubmed: 32025013
pmcid: 7054212
doi: 10.1038/s41586-019-1907-7
Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225–233 (2014).
pubmed: 24487277
pmcid: 4636053
doi: 10.1038/ng.2891
Gibson, W. J. et al. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat. Genet. 48, 848–855 (2016).
pubmed: 27348297
pmcid: 4963271
doi: 10.1038/ng.3602
Yates, L. R. et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell 32, 169–184 (2017).
pubmed: 28810143
pmcid: 5559645
doi: 10.1016/j.ccell.2017.07.005
André, F. et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380, 1929–1940 (2019).
pubmed: 31091374
doi: 10.1056/NEJMoa1813904
Varkaris, A. et al. Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations. Cancer Discov. 14, 227–239 (2024).
Fell, J. B. et al. Identification of the clinical development candidate, a covalent KRAS inhibitor for the treatment of cancer. J. Med. Chem. 63, 6679–6693 (2020).
pubmed: 32250617
doi: 10.1021/acs.jmedchem.9b02052
Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217–223 (2019).
pubmed: 31666701
doi: 10.1038/s41586-019-1694-1
Mateo, J. et al. A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 23, 5981–5992 (2017).
pubmed: 28645941
doi: 10.1158/1078-0432.CCR-17-0725
Chopra, N. et al. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nat. Commun. 11, 2662 (2020).
pubmed: 32471999
pmcid: 7260192
doi: 10.1038/s41467-020-16142-7
Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
pubmed: 15829967
doi: 10.1038/nature03445
Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).
pubmed: 19553641
doi: 10.1056/NEJMoa0900212
Konstantinopoulos, P. A. et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Oncol. 28, 3555–3561 (2010).
pubmed: 20547991
pmcid: 2917311
doi: 10.1200/JCO.2009.27.5719
Purwar, R. et al. Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials. World J. Surg. Oncol. 21, 157 (2023).
pubmed: 37217940
pmcid: 10204292
doi: 10.1186/s12957-023-03027-4
Everall, A. et al. Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types from 10,983 cancer patients. Preprint at medRxiv https://doi.org/10.1101/2023.06.07.23290970 (2023).
Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353–1365 (2020).
pubmed: 32919526
doi: 10.1016/S1470-2045(20)30445-9
Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. https://doi.org/10.1200/po.17.00011 (2017).
Shimada, K., Bachman, J. A., Muhlich, J. L. & Mitchison, T. J. shinyDepMap, a tool to identify targetable cancer genes and their functional connections from Cancer Dependency Map data. eLife 10, e57116 (2021).
pubmed: 33554860
pmcid: 7924953
doi: 10.7554/eLife.57116
Mitsopoulos, C. et al. canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Res. 49, D1074–D1082 (2020).
pmcid: 7778970
doi: 10.1093/nar/gkaa1059
Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010).
pubmed: 20871596
pmcid: 3010259
doi: 10.1038/nature09504
Zhao, Y., Aguilar, A., Bernard, D. & Wang, S. Small-molecule inhibitors of the MDM2-p53 protein–protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment. J. Med. Chem. 58, 1038–1052 (2015).
pubmed: 25396320
doi: 10.1021/jm501092z
Burns, C. G., Ohi, R., Krainer, A. R. & Gould, K. L. Evidence that Myb-related CDC5 proteins are required for pre-mRNA splicing. Proc. Natl Acad. Sci. USA 96, 13789–13794 (1999).
pubmed: 10570151
pmcid: 24143
doi: 10.1073/pnas.96.24.13789
Freedman, A. N. et al. Use of next-generation sequencing tests to guide cancer treatment: results from a nationally representative survey of oncologists in the United States. JCO Precis. Oncol. https://doi.org/10.1200/PO.18.00169 (2018).
doi: 10.1200/PO.18.00169
pubmed: 35135159
pmcid: 9797241
National Genomic Test Directory (NHS England, accessed 7 February 2023); https://www.england.nhs.uk/publication/national-genomic-test-directories/
Michaeli, D. T. & Michaeli, T. Overall survival, progression-free survival and tumor response benefit supporting initial US Food and Drug Administration approval and indication extension of new cancer drugs, 2003–2021. J. Clin. Oncol. 40, 4095–4106 (2022).
pubmed: 35921606
doi: 10.1200/JCO.22.00535
Kim, Y. et al. High-throughput functional evaluation of human cancer-associated mutations using base editors. Nat. Biotechnol. 40, 874–884 (2022).
pubmed: 35411116
pmcid: 10243181
doi: 10.1038/s41587-022-01276-4
Xiao, W. et al. Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing. Nat. Biotechnol. 39, 1141–1150 (2021).
pubmed: 34504346
pmcid: 8506910
doi: 10.1038/s41587-021-00994-5
Ansari-Pour, N. et al. Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nat. Commun. 12, 6946 (2021).
Hoang, M. L. et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci. Transl. Med. 5, 197ra102 (2013).
pubmed: 23926200
pmcid: 3973132
doi: 10.1126/scitranslmed.3006200
Prasad, V. Perspective: the precision-oncology illusion. Nature 537, S63 (2016).
pubmed: 27602743
doi: 10.1038/537S63a
Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
pubmed: 23396013
pmcid: 3833702
doi: 10.1038/nbt.2514
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).
pubmed: 34265844
pmcid: 8371605
doi: 10.1038/s41586-021-03819-2
Faure, A. J. et al. Mapping the energetic and allosteric landscapes of protein binding domains. Nature 604, 175–183 (2022).
pubmed: 35388192
doi: 10.1038/s41586-022-04586-4
Singh, J., Petter, R. C., Baillie, T. A. & Whitty, A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10, 307–317 (2011).
pubmed: 21455239
doi: 10.1038/nrd3410
Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98, 8554–8559 (2001).
pubmed: 11438690
pmcid: 37474
doi: 10.1073/pnas.141230798
Brady, S. W., Gout, A. M. & Zhang, J. Therapeutic and prognostic insights from the analysis of cancer mutational signatures. Trends Genet. 38, 194–208 (2022).
pubmed: 34483003
doi: 10.1016/j.tig.2021.08.007
Gross, G., Waks, T. & Eshhar, Z. Expression of immunoglobulin–T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86, 10024–10028 (1989).
pubmed: 2513569
pmcid: 298636
doi: 10.1073/pnas.86.24.10024
June, C. H., O'Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361–1365 (2018).
pubmed: 29567707
doi: 10.1126/science.aar6711
Hundal, J. et al. pVAC-Seq: a genome-guided in silico approach to identifying tumor neoantigens. Genome Med. 8, 11 (2016).
pubmed: 26825632
pmcid: 4733280
doi: 10.1186/s13073-016-0264-5
Sarkizova, S. et al. A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat. Biotechnol. 38, 199–209 (2020).
pubmed: 31844290
doi: 10.1038/s41587-019-0322-9
Schwarze, K. et al. The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom. Genet. Med. 22, 85–94 (2019).
pubmed: 31358947
pmcid: 6944636
doi: 10.1038/s41436-019-0618-7
Do, H. & Dobrovic, A. Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. Clin. Chem. 61, 64–71 (2015).
pubmed: 25421801
doi: 10.1373/clinchem.2014.223040
Wong, S. Q. et al. Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med. Genomics 7, 23 (2014).
pubmed: 24885028
pmcid: 4032349
doi: 10.1186/1755-8794-7-23
Li, Y. et al. Patterns of somatic structural variation in human cancer genomes. Nature 578, 112–121 (2020).
pubmed: 32025012
pmcid: 7025897
doi: 10.1038/s41586-019-1913-9
Kosugi, S. et al. Comprehensive evaluation of structural variation detection algorithms for whole genome sequencing. Genome Biol. 20, 117 (2019).
pubmed: 31159850
pmcid: 6547561
doi: 10.1186/s13059-019-1720-5
Amarasinghe, S. L. et al. Opportunities and challenges in long-read sequencing data analysis. Genome Biol. 21, 30 (2020).
pubmed: 32033565
pmcid: 7006217
doi: 10.1186/s13059-020-1935-5
Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23, 517–525 (2017).
pubmed: 28288110
pmcid: 5833945
doi: 10.1038/nm.4292
Salipante, S. J., Scroggins, S. M., Hampel, H. L., Turner, E. H. & Pritchard, C. C. Microsatellite instability detection by next generation sequencing. Clin. Chem. 60, 1192–1199 (2014).
pubmed: 24987110
doi: 10.1373/clinchem.2014.223677
Nguyen, B. et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell 185, 563–575 (2022).
pubmed: 35120664
pmcid: 9147702
doi: 10.1016/j.cell.2022.01.003
Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941–D947 (2019).
pubmed: 30371878
doi: 10.1093/nar/gky1015
Orchard, S. et al. The MIntAct project–IntAct as a common curation platform for 11 molecular interaction databases. Nucleic Acids Res. 42, D358–D363 (2014).
pubmed: 24234451
doi: 10.1093/nar/gkt1115
Hornbeck, P. V. et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 43, D512–D520 (2015).
pubmed: 25514926
doi: 10.1093/nar/gku1267
Caulfield, M. et al. National Genomic Research Library [Dataset]. figshare https://doi.org/10.6084/m9.figshare.4530893.v7 (2017).
Lärkeryd, A. instituteofcancerresearch/cansar-ddn: v0.1.0 (v0.1.0). Zenodo https://doi.org/10.5281/zenodo.8329054 (2023).
Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
pubmed: 14597658
pmcid: 403769
doi: 10.1101/gr.1239303